INT1216

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1976
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 2.65
Pain Relevance 2.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde4b) signal transduction (Pde4b) nucleus (Pde4b)
cytoplasm (Pde4b)
Anatomy Link Frequency
leukocytes 1
brain 1
neutrophil 1
Pde4b (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 7 99.84 Very High Very High Very High
fluoxetine 10 99.14 Very High Very High Very High
cytokine 10 98.44 Very High Very High Very High
monoamine 3 95.16 Very High Very High Very High
aspirin 20 93.96 High High
antidepressant 8 92.72 High High
cINOD 2 91.36 High High
Dopamine 3 91.16 High High
ischemia 1 85.40 High High
Morphine 1 73.76 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 9 99.84 Very High Very High Very High
Urological Neuroanatomy 6 99.84 Very High Very High Very High
Cv Unclassified Under Development 4 94.96 High High
Myocardial Infarction 2 88.44 High High
Reperfusion Injury 2 86.16 High High
Coronary Artery Disease 1 85.40 High High
Necrosis 4 83.48 Quite High
Cancer 4 83.12 Quite High
Schizophrenia 1 82.56 Quite High
Manic Depressive Disorder 1 81.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
PDE4B subtypes were similarly reduced in FC following treatment with clozapine, fluoxetine, and lithium.
Negative_regulation (reduced) of PDE4B associated with urological neuroanatomy and fluoxetine
1) Confidence 0.41 Published 2010 Journal Synapse Section Abstract Doc Link 20222156 Disease Relevance 0.78 Pain Relevance 0.19
Chronic fluoxetine treatment increased PDE4A mRNA levels and decreased those for PDE4B, PDE4D and PDE4D1 mRNAs in some brain regions.
Negative_regulation (decreased) of PDE4B in brain associated with fluoxetine
2) Confidence 0.39 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12504921 Disease Relevance 0 Pain Relevance 0.85
Inhibition of type IV phosphodiesterase (PDE IV) activity reduces the production of various proinflammatory cytokine and suppresses neutrophil activation.
Negative_regulation (Inhibition) of PDE IV in neutrophil associated with cytokine
3) Confidence 0.15 Published 2005 Journal Dig. Dis. Sci. Section Abstract Doc Link 15986861 Disease Relevance 0.31 Pain Relevance 0.40
The drugs used were pimobendan, a selective PDE III inhibitor, rolipram, a selective PDE IV inhibitor, and zaprinast, a selective PDE V inhibitor.
Negative_regulation (inhibitor) of PDE IV
4) Confidence 0.14 Published 2003 Journal Eur J Anaesthesiol Section Abstract Doc Link 12650491 Disease Relevance 0.17 Pain Relevance 0
The specific PDE IV inhibitor rolipram is known to be a potent inhibitor of inflammation by increasing intracellular cyclic AMP in leukocytes.
Negative_regulation (inhibitor) of PDE IV in leukocytes associated with inflammation
5) Confidence 0.11 Published 2005 Journal Dig. Dis. Sci. Section Abstract Doc Link 15986861 Disease Relevance 0.36 Pain Relevance 0.56
The drugs used were pimobendan, a selective PDE III inhibitor, rolipram, a selective PDE IV inhibitor, and zaprinast, a selective PDE V inhibitor.
Negative_regulation (inhibitor) of PDE IV
6) Confidence 0.10 Published 2003 Journal Eur J Anaesthesiol Section Abstract Doc Link 12650491 Disease Relevance 0.17 Pain Relevance 0
Three groups of rats were studied: vehicle controls (n=6); positive controls for infarct size reduction (ischemic preconditioning; n=6); and a group treated with the selective inhibitor of PDE-IV and TNF-alpha production, rolipram (1 mg/kg i.v. 10-min prereperfusion + 1 microg/kg per minute through 1-hr reperfusion, n=6). 4.
Negative_regulation (inhibitor) of PDE-IV
7) Confidence 0.07 Published 1999 Journal Gen. Pharmacol. Section Abstract Doc Link 9888252 Disease Relevance 0.65 Pain Relevance 0.04
Unlike d-amphetamine, both imipramine and nomifensine inhibited the cyclic AMP phosphodiesterase activity at concentrations more than 10(-4)M.
Negative_regulation (inhibited) of cyclic AMP phosphodiesterase
8) Confidence 0.06 Published 1976 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 178070 Disease Relevance 0 Pain Relevance 0.46
Furthermore, PASMC receiving the combination of a PDE3 and a PDE4 inhibitor exhibited a significant additive or synergistic anti-mitogenic effect as compared to each PDE inhibitor used on its own.
Negative_regulation (inhibitor) of PDE4
9) Confidence 0.03 Published 2005 Journal Respir Res Section Body Doc Link PMC1291406 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox